Thrombosis Journal
Thrombosis Journal is the official journal of the Asian-Pacific Society on Thrombosis and Hemostasis.
Members of APSTH are entitled to a 15% discount on the article processing charge.
State of the Art 2016: Research and Review from the 9th Congress of the Asian-Pacific Society on Thrombosis and Hemostasis
Reviews
Publication of this supplement was funded by APSTH 2016. The articles have undergone the journal's standard peer review process for supplements. The Supplement Editors declare that they have no competing interests.
Taipei, Taiwan
6-9 October 2016
Edited by Ming-Ching Shen, Shu-Wha Lin, Ching-Ping Tseng and Jiaan-Der Wang.
- INTRODUCTIONThrombosis Journal 2016 14(Suppl 1):37Published on: 4 October 2016
- RESEARCH
De novo mutation and somatic mosaicism of gene mutation in type 2A, 2B and 2M VWD
Von Willebrand disease (VWD) is not uncommon in Taiwan. In type 2 or type 3 VWD hemorrhagic symptoms are severer and laboratory data relatively more distinctive. De novo mutation and somatic mosaicism of type 2 V...Thrombosis Journal 2016 14(Suppl 1):36Published on: 4 October 2016 - RESEARCH
Aspirin plus tirofiban inhibit the thrombosis induced by Russell’s viper venom
Thrombosis and coagulopathy are the commonest hematological manifestations of envenomation of Russell’s viper venom (RVV). Factor X is activated by a factor X-activating enzyme from Russell’s viper venom (RVV-...Thrombosis Journal 2016 14(Suppl 1):38Published on: 4 October 2016 - RESEARCH
Characteristics of Taiwanese patients of PNH in the international PNH registry
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare and acquired hematopoietic stem cell disease, with florid clinical presentations. Although this disease has been characterized in the western countries, its ...Thrombosis Journal 2016 14(Suppl 1):39Published on: 4 October 2016 - REVIEW
Thrombopoietin and its receptor in normal and neoplastic hematopoiesis
Thrombopoietin was posited to exist in 1958 and cloned in 1994, and in the ensuing two decades we have learned a great deal about the physiology and pathology of the primary regulator of thrombopoiesis. This p...Thrombosis Journal 2016 14(Suppl 1):40Published on: 4 October 2016 - REVIEW
New horizon in platelet function: with special reference to a recently-found molecule, CLEC-2
Platelets play a key role in the pathophysiological processes of hemostasis and thrombus formation. However, platelet functions beyond thrombosis and hemostasis have been increasingly identified in recent year...Thrombosis Journal 2016 14(Suppl 1):27Published on: 4 October 2016 - REVIEW
Platelets and platelet adhesion molecules: novel mechanisms of thrombosis and anti-thrombotic therapies
Platelets are central mediators of thrombosis and hemostasis. At the site of vascular injury, platelet accumulation (i.e. adhesion and aggregation) constitutes the first wave of hemostasis. Blood coagulation, ...Thrombosis Journal 2016 14(Suppl 1):29Published on: 4 October 2016 - REVIEW
The adaptor protein Disabled-2: new insights into platelet biology and integrin signaling
Multiple functions of platelets in various physiological and pathological conditions have prompted considerable attention on understanding how platelets are generated and activated. Of the adaptor proteins tha...Thrombosis Journal 2016 14(Suppl 1):28Published on: 4 October 2016 - REVIEW
Different impact of factor VIII products on inhibitor development?
Inhibitors are the most serious side effect of haemophilia treatment; they occur in 25–30 % of all patients with severe haemophilia A. Over the last 2 decades, conflicting data on the impact of clotting produc...Thrombosis Journal 2016 14(Suppl 1):31Published on: 4 October 2016 - REVIEW
Aspects of prophylactic treatment of hemophilia
Retrospective and prospective studies unambiguously show that prophylactic treatment of severe hemophilia A or B should be started as primary prophylaxis at 1–2 years’ of age and ideally before the first joint...Thrombosis Journal 2016 14(Suppl 1):30Published on: 4 October 2016 - REVIEW
Individualized prophylaxis for optimizing hemophilia care: can we apply this to both developed and developing nations?
Prophylaxis is considered optimal care for hemophilia patients to prevent bleeding and to preserve joint function thereby improving quality of life (QoL). The evidence for prophylaxis is irrefutable and is the...Thrombosis Journal 2016 14(Suppl 1):32Published on: 4 October 2016 - REVIEW
Comorbidities of cardiovascular disease and cancer in hemophilia patients
As life expectancy greatly increases in persons with hemophilia (PWH), more age-related diseases such as cancer and cardiovascular disease (CVD) emerge among this patient group. The aim of this study was to re...Thrombosis Journal 2016 14(Suppl 1):34Published on: 4 October 2016 - REVIEW
Preimplantation genetic diagnosis of hemophilia A
Preimplantation genetic diagnosis (PGD) is a powerful tool to tackle the transmission of monogenic inherited disorders in families carrying the diseases from generation to generation. It currently remains a ch...Thrombosis Journal 2016 14(Suppl 1):33Published on: 4 October 2016 - REVIEW
Extravascular FIX and coagulation
This review summarizes the evidence that collagen IV binding is physiologically important, and that the extravascular compartment of FIX is composed of type IV collagen. As we have previously demonstrated, 7 d...Thrombosis Journal 2016 14(Suppl 1):35Published on: 4 October 2016 - REVIEW
Hemophilia A gene therapy via intraosseous delivery of factor VIII-lentiviral vectors
Current treatment of hemophilia A (HemA) patients with repeated infusions of factor VIII (FVIII; abbreviated as F8 in constructs) is costly, inconvenient, and incompletely effective. In addition, approximately 25...Thrombosis Journal 2016 14(Suppl 1):41Published on: 4 October 2016 - REVIEW
Current animal models of hemophilia: the state of the art
Hemophilia is the most well-known hereditary bleeding disorder, with an incidence of one in every 5000 to 30,000 males worldwide. The disease is treated by infusion of protein products on demand and as prophyl...Thrombosis Journal 2016 14(Suppl 1):22Published on: 4 October 2016 - REVIEW
Management of venous thromboembolism: an update
Venous thromboembolism (VTE), which constitutes pulmonary embolism and deep vein thrombosis, is a common disorder associated with significant morbidity and mortality. Landmark trials have shown that direct ora...Thrombosis Journal 2016 14(Suppl 1):23Published on: 4 October 2016 - REVIEW
Causes of venous thrombosis
Venous thrombosis which mainly manifests as deep vein thrombosis of the leg or pulmonary embolism occurs in 1 per 1000 per year. It occurs due to interacting genetic, environmental and behavioral risk factors....Thrombosis Journal 2016 14(Suppl 1):24Published on: 4 October 2016 - REVIEW
Thrombophilia in East Asian countries: are there any genetic differences in these countries?
In recent years, genetic analyses of congenital deficiencies of three anticoagulant proteins, antithrombin, protein C (PC) and protein S (PS), in East Asian patients with venous thromboembolism (VTE) have grea...Thrombosis Journal 2016 14(Suppl 1):25Published on: 4 October 2016 - REVIEW
Cancer-associated thrombosis in Asia
Thrombosis is a common complication in cancer patients. Although the major inherited risk factors for thrombophilia are different between Asians and Caucasians, the main acquired risk factors that are associat...Thrombosis Journal 2016 14(Suppl 1):26Published on: 4 October 2016
.png)
No hay comentarios:
Publicar un comentario